SCHEMBL30250160

SCHEMBL30250160

COc1ccc(-c2ccc(/C=C3\SC(=S)NC3=O)cc2)cc1

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A2 P19784 1/20 0.92
▸ CLK1 P49759 1/20 0.92
▸ CSNK2B P67870 1/20 0.92
▸ CSNK2A1 P68400 1/20 0.92
▸ DYRK1A Q13627 1/20 0.92
▸ DYRK1B Q9Y463 1/20 0.92
▸ PIM1 P11309 2/20 0.71
▸ AKR1B1 P15121 1/20 0.71
▸ PIM2 Q9P1W9 1/20 0.71
▸ NPC1 O15118 1/20 0.71
▸ RAB9A P51151 1/20 0.71
▸ NAT1 P18440 4/20 0.70
▸ ADAMTS5 Q9UNA0 2/20 0.66
▸ POLB P06746 2/20 0.65
▸ MEN1 O00255 1/20 0.65
▸ BLM P54132 1/20 0.65
▸ KMT2A Q03164 1/20 0.65
▸ NOD2 Q9HC29 1/20 0.65
▸ MMP3 P08254 1/20 0.65
▸ MMP13 P45452 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15421331 0.96 CSNK2A2 (1.00) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL8312399 0.96 CSNK2A2 (1.00) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL8312402 0.96 CSNK2A2 (1.00) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL18103036 0.87 MEN1 (0.71) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL8312114 0.87 ADAMTS5 (0.75) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL4050762 0.85 HPGD (0.82) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL4050763 0.85 HPGD (0.82) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL1247708 0.84 PIM1 (1.00) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL1247705 0.84 PIM1 (1.00) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL2546911 0.84 PIM1 (1.00) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023039170-A1 SELECTIVE TARGETING OF CD38 ACTIVITY AS AN IMMUNOSTIMULATORY AND ANTITUMOR STRATEGY MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2023-03-16 — — WO disclosed
Send feedback